Home > Oncology > ESMO 2021 > Breast Cancer > Double-positive results for triple-negative metastatic breast cancer

Double-positive results for triple-negative metastatic breast cancer

Presented By
Prof. Hope Rugo, University of California, San Francisco, USA
ESMO 2021
Phase 3, KEYNOTE-355
According to results of the KEYNOTE-355 trial, adding pembrolizumab to first-line chemotherapy led to statistically significant improvement in the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) among patients with PD-L1-positive metastatic triple-negative breast cancer. Patients had 27% reduced risk for death, although this was only true for the subset of patients with clearly PD-L1-positive tumours. Prof. Hope Rugo (University of California, San Francisco, USA) presented the data from the randomised, placebo-controlled, double-blind, phase 3 KEYNOTE-355 trial (NCT02819518), in which untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer were randomised 2:1 to pembrolizumab (200 mg every 3 weeks) plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin, n=566) or placeb...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on